According to a 2024 study by the American Cancer Society, only about 20% of eligible individuals in the United States underwent lung cancer screening. The report estimates that full participation could prevent approximately 62,110 lung cancer deaths over five years, emphasizing the need for improved early detection. In response, Tempus AI, Inc. has partnered with Median Technologies to integrate its AI-based eyonis LCS solution into the Tempus Pixel platform, enabling non-invasive characterization of lung nodules.
Additionally, Tempus recently received 510(k) clearance from the U.S. FDA for its Tempus ECG-Low EF software, which identifies patients with low left ventricular ejection fraction. In 2022, the company strengthened its imaging capabilities through the acquisition of Arterys, enhancing its imaging tools across various modalities, including lung CT scans and cardiac MRIs.
In financial metrics, Tempus shares have declined 14.3% over the past year, while the industry average dropped 33.6%. Currently, Tempus trades at a forward Price-to-Sales (P/S) ratio of 6.45x, compared to the industry average of 5.66x.
